Pharming Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs
Costs for conversion of Ordinary Shares into ADS s waived by JP Morgan Chase for initial four weeks after today
LEIDEN, Netherlands, Dec. 22, 2020 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM), a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs, today separately announced that in connection with the listing of American Depositary Shares ( ADSs ) representing ordinary shares of nominal value of €0.01 each in the capital of the Company ( Ordinary Shares ) on the Nasdaq Global Market ( Nasdaq ), the United States Securities and Exchange Commission has declared effective registration statements on Form F-1 and F-6 with respect to such securities, Nasdaq has approved the ADSs for listing, and ADSs will begin tra
Each ADS represents 10 ordinary shares
The Company s ordinary shares continue to trade on Euronext Amsterdam
No new shares issued in connection with the Nasdaq listing
LEIDEN, Netherlands, Dec. 22, 2020 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM) announces that, effective today, its American Depositary Shares ( ADSs ) have been admitted for listing on the Nasdaq Global Market ( Nasdaq ) under the symbol PHAR and will begin trading tomorrow; Wednesday 23 December. Each ADS represents 10 of the Company s ordinary shares of €0.01 nominal value ( Ordinary Shares ).
The United States Securities and Exchange Commission ( SEC ) has also declared effective the Company s registration statements on Form F-1 and Form F-6, each filed with the SEC.
Pharming Announces Instructions for Exchanging Listed Ordinary Shares into Nasdaq Listed ADSs | ANP Pers Support perssupport.nl - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from perssupport.nl Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
BILTHOVEN, Netherlands, Dec. 22, 2020 /PRNewswire/ Intravacc, one of the world s leading translational research and development vaccine organisations, with an extensive track record in developing infectious diseases vaccines, today announced that it will become a Public Shareholding Company with limited liability (B.V.) as of January 1
st, 2021. The Dutch State will be sole shareholder. Until now Intravacc has been separate entity under the responsibility of the Dutch Ministry of Health, Welfare and Sport.
As a result of this privatization process, all assets, employees, intellectual property, and contracts and agreements will be transferred to the new company on January 1
Pharming Reports on Extraordinary General Meeting of Shareholders
LEIDEN, Netherlands, Dec. 11, 2020 /PRNewswire/ Pharming Group N.V. ( Pharming or the Company ) (Euronext Amsterdam: PHARM) announces that at its Extraordinary General Meeting of shareholders (EGM), held today, all proposals were approved. As a result, the one-tier board structure has become effective, and Barbara Yanni and Mark Pykett have been appointed as non-executive board members.
A recording of the webcast and the presentation slides from today s EGM are available on the Company s website: https://www.pharming.com/investors/shareholder-meetings
About Pharming Group N.V.
Pharming Group N.V. is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.